Search

Amaç: Kronik myeloid lösemi (KML), bcr-abl füzyon geninin pozitifliği ile karakterize olan myeloproliferatif bir hastalıktır. Oksidatif stres bu hastalarda DNA hasarına yol açarak hastalığın patogenezinde rol oynuyor olabilir. Thiol molekülleri organizmayı oksidatif stresin zararlı etkilerinden korumaktadır. Biz de bu çalışmamızda KML hastalarında thiol/disülfit dengesinin durumunu araştırmayı amaçladık. Yöntem: Toplam 48 hasta ve 80 sağlıklı birey çalışmaya dahil edildi. Alınan venöz kan örnekleri santrifüj edilerek ayrılan serum kısmı -800C’de tüm örnekler çalışılana kadar saklandı. Bu kan örneklerinden native thiol, total thiol, disülfit ve İskemi modifiye albümin (İMA) çalışıldı. Bulgular: Hastaların medyan Sokal skoru 0.78 (0.56-1.37) olarak hesaplandı. Sokal skor kategorilerinde native thiol, total thiol, disülfit/native thiol, disülfit/total thiol, native thiol/total thiol ve İMA düzeyleri arasında anlamlı farklılık tespit edilmiştir. Hasta ve kontrol grubu oksidatif stres ölçümü bakımından karşılaştırıldığında, hastalardaki ölçümler artmış oksidatif stres ile uyumlu bulunmuştur. Sokal skoruna göre yüksek risk grubunda yer alan hastalarda serum İMA düzeylerinin anlamlı derecede daha yüksek olduğu görülmüş ve risk arttıkça İMA düzeylerinde de anlamlı düzeyde artış olduğu görülmüştür (p

Objective: There are some studies about the significance of the peripheral blood parameters in breast cancer. However, there is very few studies about prognostic importance of peripheral blood parameters in human epidermal growth factor-2 receptor (Her-2) positive breast cancer. We aimed to evaluate whether prognostic significance of peripheral blood parameters in patients Her-2 positive metastatic breast cancer with treated Pertuzumab, Trastuzumab, Docetaxel (PTD) Material and Methods: We included 56 patients with Her-2 positive metastatic breast cancer patients who were treated with PTD. We recorded patients' clinical,demographic features and we obtained peripheral blood parameters such as neutrophil-lymphocyte ratio (NLR), red blood cell distribution (RDW), mean platelet volume (MPV), lymphocyte, neutrophil after the sixth cycle of the treatment and before the treatment. We separated the patients into two groups depending on the progression status. Progression-free survival was analyzed by Kaplan-Meier statistical analysis. Results: Patients mean age was 50.7. Progression was detected in 34 patients. When we explored and compared hemogram parameters in the groups before the treatment, there wasn’t statistically any significant difference between these parameters such as neutrophil, lymphocyte, neutrophil to lymphocyte ratio, mean platelet volume, red blood cell width. In the progressive group;,while pretreatment NLR was 3.83, it was detected 2.72 after six cycle treatment and difference was meaningful ( p: 0.043). The pretreamtent MPV was 8.63, and It was 8.15 after six cycle treatment, and difference between these counts was statistically important (p: 0.006). PFS was 18.0 months in the study group. Conclusion: Peripheral blood parameters were not statistically significant in both group comparisons. In the progression group, the difference between NLR and MPV count was statistically significant after the sixth cycle of the treatment and before the treatment.

Giriş: Erken evre Kolon kanserinde en önemli prognostik belirteç bölgesel Lenf Nodu (LN) metastazı durumudur. Ayrıca uygun tedavi planının yapılabilmesinin en önemli şartı da tam evrelemenin yapılmış olmasıdır. Amaç: Çalışmamızda erken evre Kolon kanserinde preoperatif Pozitron Emisyon Tomografisi (PET/BT)’nin bölgesel LN’ları ile ilşkisini incelemeyi amaçladık. Yöntemler: Kliniğimizde Mart 2014 ve Temmuz 2019 tarihleri arasında tedavi ettiğimiz 83 erken evre Kolon kanseri hastasının verilerini retrospektif olarak analiz ettik. Preoperatif PET/BT bulguları ile Patolojik evrelemedeki bulguları karşılaştırdık Bulgular: Erken evre Kolon kanserinde PET/BT’nin LN metastazını göstermede sensitivite, spesifite ve doğruluk oranını sırasıyla %66,7, %64 ve %65,1 olarak belirledik. Tartışma: Çalışmamıza göre erken evre kolon kanserinde PET/BT’nin LN metastazını göstermedeki sensitivite ve spesifitesi tatmin edici olmaktan uzaktır. Sonuç: Konu ile ilgili yayınlanmış çalışmalarda genel olarak kolon ve rektum kanserli hastalar beraber incelenmiştir. Çalışmamızda sadece Kolon kanserli hastalar incelendiğinde hasta grubu olarak daha homojendir. Bu bakımdan literatüre katkı sunabileceğimizi düşünüyoruz.

Introduction Approximately 20–33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms. Palbociclib and ribociclib are weak bases so their solubility depends on different pH. The solubility of palbociclib dramatically decreases to Patients and methods We enrolled hormone receptor-positive, HER2-negative mBC patients treated with endocrine treatment (letrozole or fulvestrant) combined palbociclib or ribociclib alone or with PPI accompanying our observational study. During palbociclib/ribociclib therapy, patients should be treated with "concurrent PPIs" defined as all or more than half of treatment with palbociclib/ribociclib, If no PPI was applied, it was defined as ‘no concurrent PPI’, those who used PPI but less than half were excluded from the study. All data was collected from real-life retrospectively. Results Our study included 217 patients, 105 of whom received palbociclib and 112 received ribociclib treatment. In the study population CDK inhibitor treatment was added to fulvestrant 102 patients ( 47%), to letrozole 115 patients (53%). In the Palbociclib arm fulvestrant/letrozole ratio was 53.3/46.7%, in the ribociclib arm it was 41.07/58.93%. Of 105 patients who received palbociclib, 65 were on concomitant PPI therapy, 40 were not. Of the 112 patients who received ribociclib, 61 were on concomitant PPI therapy, 51 were not. In the palbociclib group, the PFS of the patients using PPIs was shorter than the PFS of the patients not using (13.04 months vs. unreachable, p p p = 0.003). It was determined that taking PPIs was single statistically independent predictor of shortening PFS (p = 0.003, univariate analysis). Conclusions Our study demonstrated that concomitant usage of PPIs was associated with shorter PFS in mBC treated with both ribociclib and especially palbociclib. If it needs to be used, PPI selection should be made carefully and low-strength PPI or other ARAs (eg H2 antagonists, antacids) should be preferred.

Here, we present a 45-year-old woman with endometrial cancer who presented with hyperemesis, vomiting and loss of consciousness. The serum calcium concentration was 18.3 mg/dl and bone scintigraphy revealed no evidence of skeletal involvement by the tumor. Her parathyroid hormone (PTH) level was normal, but the parathyroid hormone-related peptide (PTHrP) level was higher than the normal values. Through our case, we review the treatment of malignant hypercalcemia. Turk Jem 2013; 17: 8-11

rare condition in which two histologically distinct neoplasms grow concurrently in the same locationdein a 64-year-old male patient, with sharply defined borders. Adenocarcinomas are the most common tumours of the stomach. Other types of tumours can occasionally accompany gastric adenocarcinomas. Foci of adenocarcinoma and neuroendocrine carcinoma were identified in adjacent areas in a 64-year-old male patient who had undergone total gastrectomy due to adenocarcinoma of the gastric cardia. Of the seven metastatic lymph nodes, three were affected by adenocarcinoma and four were affected by neuroendocrine carcinoma. Based on this patient case, we discussed gastric collision tumours in the light of the literature.